title: A clinicopathological study of episomal papillomavirus infection of the human placenta and pregnancy complications.
abstract: Viral infections are known to adversely affect pregnancy, but scant attention has been given to human papilloma virus (HPV) infection. We aimed to determine the molecular and histopathological features of placental HPV infection, in association with pregnancy complications including fetal growth restriction, pre-maturity, pre-eclampsia, and diabetes. Three hundred and thirty-nine placentae were selected based on the presence or absence of pregnancy complications. Five independent methods were used to identify HPV in the placenta, namely, immunohistochemistry for L1 viral capsid, in situ hybridization to high-risk HPV DNA, PCR, western blotting, and transmission electron microscopy. Pregnancy complications and uterine cervical smear screening results were correlated with placental HPV histopathology. In this study, which was deliberately biased towards complications, HPV was found in the decidua of 75% of placentae (253/339) and was statistically associated with histological acute chorioamnionitis (P<0.05). In 14% (35/253) of the HPV positive cases, HPV L1 immunoreactivity also occurred in the villous trophoblast where it was associated with a lymphohistiocytic villitis (HPV-LHV), and was exclusively of high-risk HPV type. HPV-LHV significantly associated with fetal growth restriction, preterm delivery, and pre-eclampsia (all P<0.05). All cases of pre-eclampsia (20/20) in our cohort had high-risk placental HPV. A further 55 cases (22%, 55/253) of HPV positive placentae had minimal villous trophoblast HPV L1 immunoreactivity, but a sclerosing pauci-immune villitis, statistically associated with diabetes (49.1%, 27/55, P<0.05). For women with placental HPV, 33% (69/207) had an HPV-related positive smear result before pregnancy compared with (9.4% 8/85) of women with HPV-negative placentae (P=0.0001). Our findings support further investigations to determine if vaccination of women and men will improve pregnancy outcomes.
authors: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
authors: Tania L
authors: TL
authors: Slatter
authors: Kings College London, Strand, London, UK.
authors: Natalie Gly
authors: NG
authors: Hung
authors: Women's and Children's Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
authors: William M
authors: WM
authors: Clow
authors: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
authors: Janice A
authors: JA
authors: Royds
authors: Women's and Children's Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
authors: Celia J
authors: CJ
authors: Devenish
authors: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
authors: Noelyn A
authors: NA
authors: Hung
mesh_terms: D000328:Adult; D015153:Blotting, Western; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D046529:Microscopy, Electron, Transmission; D030361:Papillomavirus Infections / Q000150:complications* / Q000473:pathology; D010920:Placenta / Q000473:pathology / Q000821:virology*; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000473:pathology / Q000821:virology*; D011256:Pregnancy Outcome